Tylenol Gains On COX-2 Fallout, Drives J&J Consumer Sales
This article was originally published in The Tan Sheet
Tylenol first-quarter sales benefited from the publicity surrounding COX-2 safety issues, according to Johnson & Johnson
You may also be interested in...
Extra Strength Rapid Release Gels "have specially designed holes in the gelcap that allow the medicine to be released more quickly than before," McNeil announces. The gels are rolling out now at food, drug and mass retailers in 24-, 50- and 100-count packages with SRPs of $4.99, $6.00 and $9.99, respectively. Rapid Release will be backed by a national campaign. Tylenol Allergy Complete (acetaminophen, chlorpheniramine maleate and pseudoephedrine HCl) features the brand's Cool Burst coating to provide "an instant cooling sensation upon administration of the medicine." The 24-and 48-count packages will cost $5.99 and $8.99 when they hit shelves in March, supported by radio and an April 3 FSI drop...
Merck says it will seek new partners for future Rx-to-OTC switch drugs in Europe following Johnson & Johnson's buyout of the company's half of their European consumer health joint venture
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC